Infection with human papillomavirus (HPV) type 16 accounts for about half of cervical
cancers worldwide. This study investigated the seroepidemiology of HPV-16 infection in the …

Background. The study sought to characterize the seroprevalence, seropersistence, and
seroincidence of human papillomavirus (HPV)-16 antibody, as well as the behavioral risk …

We evaluated the prevalence of antibodies to human papillomavirus (HPV) type 16 in a
representative sample of children 6–11 years of age in the United States. Serum samples …

A human papillomavirus type 16 (HPV-16) virus-like particle (VLP)-based enzyme-linked
immunosorbent assay (ELISA) was used to measure serum antibody to capsid proteins in …

Background Previous studies have demonstrated that genital infection with high-risk types of
human papillomavirus (HPV), most often HPV16, is the most significant risk factor for the …

Background Human papillomavirus (HPV) seroprevalence data can help define the
epidemiology of this common sexually transmitted pathogen Methods We determined the …

An ELISA to detect serum IgG antibody response to human papillomavirus (HPV) type 16
viruslike particles (VLPs) was evaluated in a case-control study of cervical neoplasia, nested …

Background Infection with human papillomavirus (HPV) 16 or HPV18 elicits an antibody
response, but whether the elicited antibodies protect women against subsequent infection …

Abstract Human papillomavirus (HPV)—16 causes about half the cases of cervical cancer
worldwide and is the focus of HPV vaccine development efforts. Systematic data are lacking …

A high incidence of initial infection with human papillomavirus (HPV) was previously
reported in a cohort of 608 women monitored at 6-month intervals for 3 years. Risk factors for …